"The human gut microflora is important in regulating host immune homeostasis (9). In vivo administration of VSL#3, a probiotic preparation of live, freeze-dried bacteria containing eight bacterial species [S. salivarius subsp. thermophilus, Bifidobacterium (B. breve, B. infantis, B. longum), L. acidophilus, L. plantarum, L. casei, L. delbrueckii subsp. Bulgaricus], attenuated liver steatosis in ob/ob mice that present characteristics of NAFLD (10). Although the cellular and molecular basis of the action of probiotics is yet to be understood, some liver-related beneficial effects of VSL#3 treatment were found in a small cohort of patients with NAFLD (11)."
"Based on the features of NAFLD/NASH in humans, which include steatosis and liver inflammation followed by fibrosis (12), and based on the suggested anti-inflammatory properties of VSL#3 in animal models of chronic inflammation (10,13), we entertained the hypothesis that probiotic treatment with VSL#3 will ameliorate MCD-induced NASH by modulation of liver inflammation and/or fibrosis."
From http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3756672/
"Based on the features of NAFLD/NASH in humans, which include steatosis and liver inflammation followed by fibrosis (12), and based on the suggested anti-inflammatory properties of VSL#3 in animal models of chronic inflammation (10,13), we entertained the hypothesis that probiotic treatment with VSL#3 will ameliorate MCD-induced NASH by modulation of liver inflammation and/or fibrosis."
From http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3756672/
No comments:
Post a Comment